Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
International Journal of Radiation Oncology, Biology, Physics|September 10, 2024
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective StudyGabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2020
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)Gabriella Ferrandina, Cynthia Aristei, Pietro Raimondo Biondetti, et al.
International Journal of Radiation Oncology, Biology, Physics|April 2, 2025
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD)Gabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG StudySandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology|April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trialsGennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
The Oncologist|February 12, 2020
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO GroupsGabriella Macchia, Roberta Lazzari, Nicoletta Colombo, et al.
Oncotarget|September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACCFrancesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Gynecologic Oncology|January 25, 2024
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancerGabriella Macchia, Savino Cilla, Donato Pezzulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology|March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialSandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Pageof 30